CLR 131

Phase 1Small molecule

CCellectar Biosciences, Inc.

CLR 131 is one of 88 small molecule programs targeting Relapsed or Refractory. It is currently in Phase 1.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Relapsed or RefractoryActive, not recruiting

NeuroblastomaActive, not recruiting

Relapsed or RefractoryPhase 1

Active, not recruiting

NeuroblastomaPhase 1

Active, not recruiting

Competition

Competitive Landscape

88 competitors in Neuroblastoma

#DrugCompanyPhaseTrials

Cytoxan

BBaxter Healthcare Corporation

Phase 3

52 2

Vepesid

AAvyxa

Phase 3

40 3

Paraplatin

AAvyxa

Phase 3

35 4

Leukine

Sanofi

Phase 3

15 5

Camptosar

Pfizer

Phase 3

12 6

Tepadina

Jazz Pharmaceuticals

Phase 3

11 7

Alkeran

AApotex Inc.

Phase 3

28 8

Accutane

CConrado Roberto Hoffmann Filho

Phase 3

26 9

Oncovin

Eli Lilly

Phase 3

9 10

Adriamycin

Pfizer

Phase 3

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q1 2027

Phase 1Active, not recruiting

Neuroblastoma

NCT03478462

Q3 2029

Phase 1Recruiting

Breast Cancer

NCT07311993

Clinical

Trials by Indication[1]

Breast Cancer1 trial

Phase 1 Study of CLR 125 in Triple Negative Breast Cancer

Recruiting·CCellectar Biosciences, Inc.·Phase 1·NCT07311993·60 enrolled

Relapsed or Refractory1 trial

Novel Targeted Radiotherapy in Pediatric Patients With Inoperable Relapsed or Refractory HGG

Active, not recruiting·CCellectar Biosciences, Inc.·Phase 1·NCT05610891·50 enrolled

Neuroblastoma1 trial

Dose Escalation Study of CLR 131 in Pediatric Relapsed/Refractory Malignant Tumors Including Neuroblastoma and Sarcomas

Active, not recruiting·CCellectar Biosciences, Inc.·Phase 1·NCT03478462·30 enrolled

Head and Neck Cancer1 trial

CLR 131 Combined With Radiation for Head and Neck Cancer

Completed·UUniversity of Wisconsin, Madison·Phase 1·NCT04105543·12 enrolled

Sources

References

[1]
ClinicalTrials.gov — 4 trial records for CLR 131. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — CLR 131 compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for CLR 131. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Cellectar Biosciences, Inc. company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 1[1]
Company: CCellectar Biosciences, Inc.

CLR 131

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q1 2027

Q3 2029

Trials by Indication[1]

Breast Cancer1 trial

Relapsed or Refractory1 trial

Neuroblastoma1 trial

Head and Neck Cancer1 trial

References

Drug Info

Quick Facts

Related News